Zydus Lifesciences venture capital arm invests in Feldan Therapeutics
Pennington: Zydus Lifesciences' venture capital arm, Zynext Ventures USA LLC, has announced its investment in Feldan Therapeutics, a Canada-based early clinical-stage pharmaceutical company.
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells. The company's lead candidate, FLD-103, is administered directly into basal cell carcinoma (BCC) lesions, where the Shuttle peptide facilitates the delivery of a Hedgehog inhibitor to its target within BCC cells.
This approach aims to provide BCC patients with a non-surgical treatment option that improves outcomes. Additionally, Feldan is advancing a pulmonary program that leverages the Shuttle's unique ability to transport biomolecules into hard-to-deliver lung cells to address the unmet and growing medical needs of patients with respiratory diseases.
Speaking on the development, Dr. Sharvil Patel, MD of Zydus Lifesciences, said, “At Zydus, we are committed towards advancing the development of novel therapeutics to addressing critical gaps in healthcare through innovation. We are pleased to support Feldan in exploring a potentially safe and targeted option for patients with dermatological and pulmonary disease and help them lead a better quality of life.”
Jay Kothari, Director of Zynext Ventures, highlighted, “Feldan's platform has the potential to transform intracellular delivery and pioneer next-generation therapeutics, aligning with the disruptive innovations we aim to add to our portfolio.”
"This partnership with Zynext Ventures marks an exciting step forward in our commitment to improve patients' quality of life and address critical drug delivery challenges," said FrançoisThomas Michaud, CEO of Feldan Therapeutics. "With Zynext Ventures’ strategic expertise and shared dedication to innovation, we are well-positioned to accelerate the development of next-generation therapies."
Zynext Ventures is the investment arm of Zydus Lifesciences. The venture capital firm focuses on identifying and investing in promising early-stage and growth-stage companies in the healthcare sector. Zynext Ventures provides financial support, strategic guidance, and industry expertise to its portfolio companies.
Next Story